Palifermin biosimilar - Nanogen Biopharmaceutical

Drug Profile

Palifermin biosimilar - Nanogen Biopharmaceutical

Alternative Names: Keratinocyte growth factor - Nanogen

Latest Information Update: 19 Mar 2014

Price : $50

At a glance

  • Originator Nanogen Biopharmaceutical Co
  • Class Chemoprotectants; Fibroblast growth factors
  • Mechanism of Action Fibroblast growth factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Stomatitis

Most Recent Events

  • 19 Mar 2014 Early research in Stomatitis in Vietnam (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top